919514-01-5
919514-01-5
Chemical Structure
Duloxetine-d7
- CAS No.: 919514-01-5
- Formula:C18H12D7NOS
- Molecular Weight:304.46
IUPAC Name: (S)-N-methyl-3-((naphthalen-1-yl-d7)oxy)-3-(thiophen-2-yl)propan-1-amine
InChIKey: ZEUITGRIYCTCEM-KGAVXYHHSA-N
SMILES: O([C@@H](CCNC)C1=CC=CS1)C=2C3=C(C(=C(C2[2H])[2H])[2H])C(=C(C(=C3[2H])[2H])[2H])[2H]
Biological Activity: Duloxetine-d7 ((S)-Duloxetine-d7) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Duloxetine-d7 | 97.30% | Duloxetine-d7 ((S)-Duloxetine-d7) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Duloxetine-d5 oxalate | Duloxetine-d5 (oxalate) ((S)-Duloxetine-d5 (oxalate)) is deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Duloxetine | 99.92% | Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. De Berardis, D., et al., The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol, 2010. 23(2): p. 417-22. [Content Brief]
